cyrilzakka/clinical-trials huggingface dataset:
the Effectiveness of Brain-computer Interface-pedaling Training System on the Rehabilitation of Stroke

Stroke has become the first cause of death and disability among Chinese adults. 70%-80% of patients cannot live independently due to disability, which has brought a heavy burden to families, medical institutions and society. How to better evaluate and improve post-stroke motor and cognitive dysfunction has always been a hot research topic. With the rapid development of brain-computer interface technology, rehabilitation assessment based on quantitative EEG analysis is gradually being applied in the medical field. So we designed a brain-computer interface based on hierarchical task induction-pedaling rehabilitation training system to investigate the effectiveness on the rehabilitation of stroke patients.


Eligibility Criteria:
Inclusion Criteria:

* Aged 40-80 years old；
* Patients with first ischemic stroke onset from 1 week to 3 months；
* Hemiplegia and cognitive impairment (Mini-Mental State Examination (MMSE) score \<28 or Montreal Cognitive Assessment (MoCA) \<25)；
* Consciousness, sitting balance level 1 or above, can cooperate with assessment and treatment;
* The patient or its authorized agent signs the informed consent form.

Exclusion Criteria:

* Severely impaired cognition, unable to pay attention to and understand screen information;
* Severe pain and limited mobility of lower extremity.
Comparison of Modified Post-Anesthetic Discharge Scoring System (PADSS) Between 6 and 24 Hours in Patients Undergoing Total Knee Arthroplasty

This study is a prospective study which compares of Modified Post-Anesthetic Discharge Scoring System (PADSS) between 6 and 24 hours in patients undergoing total knee arthroplasty in Thammasat University hospital, Thailand.


Eligibility Criteria:
Inclusion Criteria:

* Patient undergoing total knee arthroplasty (one side) under spinal block with adductor canal block
* 18-85 years old
* American Society of Anesthesiologist physical status classification I-III

Exclusion Criteria:

* Allergy to local anesthetic drugs
Detecting Occult Proximal Humeral Neck Fractures Through CT and MRI Tests of Patients With Greater Tuberosity Fractures

Patients with greater tuberosity fractures is becoming increasingly common, as is the number of cases of humeral surgical neck fractures. This study investigated the relationship between size of greater tuberosity fragment and occurrence of humeral surgical neck fractures by using CT or MRI tests.

Some humeral surgical neck fractures can be detected through X-ray of shoulder in patients with greater tuberosity fractures. However, some fractures can not be find through conventional X-ray in such patients unless broader CT or MRI tests are required to confirm diagnoses of humeral surgical neck fractures.

Eligibility Criteria:
Inclusion Criteria:

* Patients 18 years or older with greater tuberosity fractures and shoulder dislocation/ or not who were acute injured were included

Exclusion Criteria:

* Patients with ipsilateral previous proximal humeral fractures and obviously proximal humeral fractures were excluded。
Experiences With New Digital Surgical Drainage System in Thoracic Surgery

The purpose of this study is to evaluate the Thoraguard Surgical Drainage System in a real-world clinical environment. It is believed that this system will offer functional and clinical benefits over the current standard of care system for the removal of surgical fluids and air following thoracic surgery. Observations, experiences, and outcomes in a single hospital setting will be collected for the Thoraguard Surgical Drainage System.

The Thoraguard System is intended for use for drainage of blood, fluids, and gases following cardiac and thoracic surgery. The system consists of an electronic control module and drainage kit (fluid collection canister and drainage line) which connect to a proprietary chest tube but may also connect to other thoracic drainage catheters. The system continuously monitors line patency, automatically clears the chest tube (when used with Thoraguard Chest Tube) and drainage line from build-up, and provides digital readings of fluid output trends. The system is battery powered with integrated suction for ease of ambulation.

Additionally, the system has patient safety alarms to notify clinical staff of unexpected events associated with postoperative drainage. These functions offer significant improvements over the current standard of care. Reliable post-operative drainage, reduced workload, and decreased variability in chest tube maintenance procedures have the potential to increase patient safety, reduce complications, and improve the patient experience.

Eligibility Criteria:
Inclusion Criteria:

* Adult (age ≥ 18)
* Patient undergoing non-emergent thoracic surgery (Sternotomy, Video-Assisted Thoracoscopic Surgery (VATS), Thoracotomy, or Robotic)
* Expected requirement for chest drain monitoring of air leak for at least 24h post-operation
* A requirement for a surgical drainage system

Exclusion Criteria:

* Emergency surgery
* Re-do surgery
* Prior thoracic surgery
* Transplant Surgery
* In the opinion of the investigator, the patient is unsuitable for the study for any other legitimate reason including incarceration, pre-existing medical or psychiatric condition, or interfering medications
* Known previous or concurrent enrollment in a clinical trial that, in the opinion of the investigator, might interfere with the objectives of this clinical trial
* Pregnancy
Health Care Workers and Mental Health

The purpose of this proposal is to deploy digital health interventions to bring timely, easily accessible resources and care to address the mental health and well-being needs of HCWs with direct patient care that are experiencing the impact of the COVID-19 pandemic and its economic, financial, and social sequelae at present and presumably for years to come. This proposal will evaluate the effectiveness of an enhanced digital mental health care delivery system (Cobalt), any differential effect by race and gender and, through qualitative interviews, how those interventions are perceived.

The purpose of this proposal is to deploy digital health interventions to bring timely, easily accessible resources and care to address the mental health and well-being needs of HCWs with direct patient care that are experiencing the impact of the COVID-19 pandemic and its economic, financial, and social sequelae at present and presumably for years to come. This proposal will evaluate the effectiveness of an enhanced digital mental health care delivery system (Cobalt), any differential effect by race and gender and, through qualitative interviews, how those interventions are perceived. No Intervention: Usual Care, Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity, hours of direct patient care, percent of time providing care for patients with COVID-19) at enrollment; 0 months, 6 months, and 9 months. Behavioral: Cobalt +: Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.

Eligibility Criteria:
Inclusion Criteria:

1. Aged 18 years or older
2. Regular, daily access to an smartphone
3. Able to communicate fluently in English
4. Work at least 4 hours per week in either a hospital or outpatient based setting. This includes health care workers like physicians, nurses, certified nursing assistants, lab technicians, radiology technicians, physical therapist, occupational therapist, pharmacists, pharmacy technicians, patient registration staff, receptionists/patient intake coordinators, environmental and food service personnel approximately 4 hours/week. This averages 192 hours/ 48 weeks in a year) in the study time frame.

Exclusion Criteria:

1. Not aged 18 years or older
2. Does not have regular, daily access to a smartphone
3. Unable to communicate fluently in English
4. Does not work at least 4 hours per week in either a hospital or outpatient based setting.
5. Not willing to sign the informed consent document
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing in adult participants with unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF where the participant has no acceptable standard treatment options.


Eligibility Criteria:
Inclusion Criteria:

* Participants with age greater than or equal to (\>=) 18 years with either unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF
* Eastern Cooperative Oncology Group Performance Status 0 to 2
* Life expectancy \>=12 weeks
* Adequate hematologic and end organ function obtained within 2 weeks prior to first dose of study drug
* Female participants of childbearing potential and male participants with partners of childbearing potential must agree to always use two effective methods of contraception including at least one method with a failure rate of \<1% per year during the course of the study and for at least 6 months after completion of study treatment
* Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential
* Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Exclusion Criteria:

* Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Study Day 1 of Period A
* Allergy or hypersensitivity to components of the vemurafenib formulation
* Experimental therapy within 4 weeks prior to first dose of study drug treatment on Study Day 1 of Period A
* Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug treatment on Study Day 1 of Period A, or anticipation of the need for major surgery during study treatment
* Prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy) within 28 days (6 weeks for nitrosoureas or mitomycin C, and 14 days for hormonal therapy or kinase inhibitors) before the first dose of study treatment on Study Day 1 of Period A.
Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postoperative pain following total hip or total knee replacement.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologist (ASA) classification 1, 2, or 3
* total hip or total knee replacement
* pain on postoperative Day 1 at least 40 mm on 0-100 mm visual analog scale (VAS)

Exclusion Criteria:

* presence of contraindications to nonsteroidal anti-inflammatory (NSAID) treatment
* recent history of angina or myocardial infarction (MI)
* clinically significant abnormality on laboratory tests or electrocardiogram (ECG)
Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology

Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity.

The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.


Eligibility Criteria:
Inclusion Criteria:

Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients.

Exclusion Criteria:

Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.
A Study to Investigate the Phototoxic Potential of Faldaprevir

To investigate the potential of Faldaprevir to induce skin phototoxicity, immediate or delayed type, to UV light and visible light in healthy male and female subjects. To investigate the degree, wavelength dependency, severity, pigmentation and morphology of the phototoxic effects. The persistence of the phototoxic susceptibility will be explored following cessation of study medication. Within a sunscreen sub-study, the efficacy of commercially available high factor sunscreen will also be assessed in terms of its potential to prevent any phototoxic skin responses seen. The safety and tolerability of Faldaprevir will also be assessed.


Eligibility Criteria:
Inclusion criteria:

* Health male and female subjects with no clinically significant abnormality (according to the Investigator's assessment) identified from a complete medical history, physical examination, whole body skin assessment, 12-lead ECG, vital signs and clinical laboratory tests. In particular, there should be no evidence of abnormal photosensitivity
* Sun-reactive skin phototype I, II, or III

Exclusion criteria:

- Any relevant deviation from healthy conditions.
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.

This is a Phase 3, randomized, double-blind, placebo-controlled, in-patient, efficacy, and safety study to evaluate HP-3070 for the treatment of schizophrenia.

This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia, who are in an acute exacerbation and to assess the impacts of covariates on asenapine exposure as delivered in a patch formulation, using a population-based approach.

Eligibility Criteria:
Inclusion Criteria:

* Current diagnosis of schizophrenia.
* Subject has PANSS total score ≥80, AND score of 4 or more in at least 2 of the following PANSS items at Screening and at Baseline: conceptual disorganization delusions; hallucinatory behavior; unusual thought content.
* Subjects must be able to wear a transdermal patch for 24 hours.

Exclusion Criteria:

* Subject has been diagnosed with schizophrenia less than 6 months prior to Screening Visit.
* Subject has received within 90 days of Screening Visit: electroconvulsive therapy; transcranial magnetic stimulation; vagal nerve stimulation; or other brain stimulation treatments
* Subject has experienced acute depressive symptoms within 30 days prior to Screening Visit that requires treatment with an antidepressant, as determined by the Investigator.
* Currently taking clozapine for the treatment of schizophrenia.
* Has hypothyroidism or hyperthyroidism.
* Subject is currently being treated with insulin for diabetes.
* Subject has epilepsy or history of seizures.
* Positive urine pregnancy test.
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis


Eligibility Criteria:
Inclusion Criteria:

* Subject was age 18 or older and in relatively good health (Investigator discretion) with a recent stable medical history.
* Subject met the definition of AS based on the Modified New York Criteria.
* Subject had an inadequate response to or intolerance to one or more NSAIDs as defined by the Investigator

Exclusion Criteria:

* Subject had previously received anti-TNF therapy.
* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
* Female subject who is pregnant or breast-feeding or considering becoming pregnant
Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe

The purpose of this study is to investigate the pharmacokinetic drug interactions between Rosuvastatin and Ezetimibe in Healthy Male Subjects


Eligibility Criteria:
Inclusion Criteria:

* Healthy male volunteer, age 19\~45 years
* The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 28 kg/m2
* Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial.

Exclusion Criteria:

* Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study
* History of relevant drug allergies or clinically significant hypersensitivity reaction.
Research on the Application of Artificial Intelligence Ultrasonic Recognition Technology in Difficult Airway Assessment

Although there is no related research on the evaluation of difficult airways by ultrasound features based on artificial intelligence, the investigators guess that the evaluation of ultrasound features based on artificial intelligence can make further breakthroughs in difficult airway early warning systems. Therefore, this project intends to use AI technology to extract and analyze the ultrasound features of the subjects, evaluate the correlation between the ultrasound features of the subjects and the occurrence of difficult airways, and construct possible diagnostic models to evaluate AI ultrasound feature recognition in the prediction of difficult airways. The effect and application value of this method are expected to be more intelligent and accurate for early warning of difficult airways in clinical anesthesia.


Eligibility Criteria:
Inclusion Criteria:

* ASA classification is 1-3
* Patients who intend to undergo tracheal intubation under general anesthesia
* Age ≥ 18 years old

Exclusion Criteria:

* Patients with speech communication and cooperation barriers;
* Patients with open head and neck trauma
* Patients with cervical spine fractures or cervical spine diseases;
* Emergency surgery;
* Patients who are allergic to related drugs.
Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection

Pivotal trials of SDC2 methylation biomarker test in stool DNA to estimate clinical sensitivity and specificity in detection of colorectal cancer.

The purpose of this study is to validate the clinical performance of EarlyTect Colon Cancer test which is measuring Syndecan 2 methylation status in stool DNA to detect CRC. Syndecan 2 (SDC2) is a newly developed methylation biomarker for colorectal cancer diagnosis. Methylation status of SDC2 gene in stool DNA is determined by methylation specific qPCR. Sensitivity and specificity will be determined by comparing Stool DNA test from healthy subjects, CRC patients, and other group including polyps and other diseases.

Eligibility Criteria:
Inclusion criteria:

* sample information is complete, including sample number, gender, family history, stage of cancer, treatment history, and other disease information
* the CRC patient who has not any treatment (surgery, chemotherapy, or radiation)
* non-CRC patient who has not received any treatment (surgery, chemotherapy, or radiation) within the last 6 months
* all of above conditions are satisfied, and any one of below can be applicable; 1) confirm to be CRC with colonoscopy and/or pathological examination, 2) confirm to be inflammatory or ulcerative bowel diseases or benign hyperplastic polyp, 3) confirm to be gastrointestinal or liver cancers who are not CRC, 4) schedule to receive colonoscopy and additional confirmation test for CRC with agreement to provide the test results.

Exclusion criteria: any one of below can be applicable;

* the patient information is not complete and/or does not satisfy inclusion criteria
* the sample information is not complete and/or does not satisfy inclusion criteria
* the CRC patient who has history of colorectal cancer surgery, chemotherapy, or any other treatment
* non-CRC patient who received any chemotherapy within the last 6 months
* the patient who has limited ability or are vulnerable to accept clinical trial agreement
* the patient who is judged as not suitable for clinical trial including a psychiatric disorder by a physician
Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients

Patients in end-stage cardiac failure and/or respiratory failure may be started on a rescue therapy known as Extracorporeal Membrane Oxygenation (ECMO). One of the major clinical questions is how to manage the ventilator when patients are on ECMO therapy. Ventilator Induced Lung Injury (VILI) can result from aggressive ventilation of the lung during critical illness. VILI and lung injury such as Acute Respiratory Distress Syndrome (ARDS) can further increase the total body inflammation and stress, this is known as biotrauma. Biotrauma is one of the mechanisms that causes multi-organ failure in critically ill patients. One advantage of ECMO is the ability to greatly reduce the use of the ventilator and thus VILI by taking control of the patient's oxygenation and acid-base status. By minimizing VILI during ECMO we can reduce biotrauma and thus multi-organ failure. Since the optimal ventilator settings for ECMO patients are not known, we plan to study the impact of different ventilator settings during ECMO on patient's physiology and biomarkers of inflammation and injury.


Eligibility Criteria:
Inclusion Criteria

* Patient currently on ECMO (Veno-Venous or Venous-Arterial or Venous-Arterial-Venous)
* Patient that is a potential ECMO candidate.

Exclusion Criteria

* History of Lung or Cardiac Transplantation
* Patient is not committed to full support
* Treating clinician refusal, or unwillingness to commit to controlled ventilation for at least 4-6 hours (if patient is mechanically ventilated)
* Inability to get informed consent from the patient or surrogate.